1126 related articles for article (PubMed ID: 15520202)
61. Transforming growth factor beta 1 (TGF beta 1) is an autocrine positive regulator of colon carcinoma U9 cells in vivo as shown by transfection of a TGF beta 1 antisense expression plasmid.
Huang F; Newman E; Theodorescu D; Kerbel RS; Friedman E
Cell Growth Differ; 1995 Dec; 6(12):1635-42. PubMed ID: 9019169
[TBL] [Abstract][Full Text] [Related]
62. TGF-beta promotes the establishment of renal cell carcinoma bone metastasis.
Kominsky SL; Doucet M; Brady K; Weber KL
J Bone Miner Res; 2007 Jan; 22(1):37-44. PubMed ID: 17032147
[TBL] [Abstract][Full Text] [Related]
63. Effect of Nma on growth inhibition by TGF-betaa in human gastric carcinoma cell lines.
Sasaki T; Sasahira T; Shimura H; Ikeda S; Kuniyasu H
Oncol Rep; 2004 Jun; 11(6):1219-23. PubMed ID: 15138559
[TBL] [Abstract][Full Text] [Related]
64. Targets of transcriptional regulation by two distinct type I receptors for transforming growth factor-beta in human umbilical vein endothelial cells.
Ota T; Fujii M; Sugizaki T; Ishii M; Miyazawa K; Aburatani H; Miyazono K
J Cell Physiol; 2002 Dec; 193(3):299-318. PubMed ID: 12384983
[TBL] [Abstract][Full Text] [Related]
65. Effector T-cell infiltration positively impacts survival of glioblastoma patients and is impaired by tumor-derived TGF-β.
Lohr J; Ratliff T; Huppertz A; Ge Y; Dictus C; Ahmadi R; Grau S; Hiraoka N; Eckstein V; Ecker RC; Korff T; von Deimling A; Unterberg A; Beckhove P; Herold-Mende C
Clin Cancer Res; 2011 Jul; 17(13):4296-308. PubMed ID: 21478334
[TBL] [Abstract][Full Text] [Related]
66. Cystatin C antagonizes transforming growth factor beta signaling in normal and cancer cells.
Sokol JP; Schiemann WP
Mol Cancer Res; 2004 Mar; 2(3):183-95. PubMed ID: 15037657
[TBL] [Abstract][Full Text] [Related]
67. EW-7195, a novel inhibitor of ALK5 kinase inhibits EMT and breast cancer metastasis to lung.
Park CY; Son JY; Jin CH; Nam JS; Kim DK; Sheen YY
Eur J Cancer; 2011 Nov; 47(17):2642-53. PubMed ID: 21852112
[TBL] [Abstract][Full Text] [Related]
68. Effects of growth factors on the antiproliferative activity of tumor necrosis factors.
Sugarman BJ; Lewis GD; Eessalu TE; Aggarwal BB; Shepard HM
Cancer Res; 1987 Feb; 47(3):780-6. PubMed ID: 3802082
[TBL] [Abstract][Full Text] [Related]
69. Attenuation of the TGF-beta-Smad signaling pathway in pancreatic tumor cells confers resistance to TGF-beta-induced growth arrest.
Nicolás FJ; Hill CS
Oncogene; 2003 Jun; 22(24):3698-711. PubMed ID: 12802277
[TBL] [Abstract][Full Text] [Related]
70. The role for transforming growth factor-beta (TGF-beta) in human cancer.
Gold LI
Crit Rev Oncog; 1999; 10(4):303-60. PubMed ID: 10654929
[TBL] [Abstract][Full Text] [Related]
71. MS-275, a histone deacetylase inhibitor, selectively induces transforming growth factor beta type II receptor expression in human breast cancer cells.
Lee BI; Park SH; Kim JW; Sausville EA; Kim HT; Nakanishi O; Trepel JB; Kim SJ
Cancer Res; 2001 Feb; 61(3):931-4. PubMed ID: 11221885
[TBL] [Abstract][Full Text] [Related]
72. Activin type II receptor restoration in ACVR2-deficient colon cancer cells induces transforming growth factor-beta response pathway genes.
Deacu E; Mori Y; Sato F; Yin J; Olaru A; Sterian A; Xu Y; Wang S; Schulmann K; Berki A; Kan T; Abraham JM; Meltzer SJ
Cancer Res; 2004 Nov; 64(21):7690-6. PubMed ID: 15520171
[TBL] [Abstract][Full Text] [Related]
73. Tumor-host interaction mediates the regression of BK virus-induced vascular tumors in mice: involvement of transforming growth factor-beta1.
Corallini A; Possati L; Trabanelli C; Giraudo E; Rocchetti R; Talevi S; Caputo A; Bussolino F; Barbanti-Brodano G
Carcinogenesis; 2003 Sep; 24(9):1435-44. PubMed ID: 12844479
[TBL] [Abstract][Full Text] [Related]
74. Interferon-gamma suppresses transforming growth factor-beta-induced invasion of gastric carcinoma cells through cross-talk of Smad pathway in a three-dimensional culture model.
Kuga H; Morisaki T; Nakamura K; Onishi H; Noshiro H; Uchiyama A; Tanaka M; Katano M
Oncogene; 2003 Oct; 22(49):7838-47. PubMed ID: 14586410
[TBL] [Abstract][Full Text] [Related]
75. [Effects of TCGF (T-cell growth factor) on experimental malignant glioma-specific killer T-cell].
Yamasaki T; Yamashita J; Handa H; Namba Y; Hanaoka M
No Shinkei Geka; 1984 Feb; 12(2):141-50. PubMed ID: 6609319
[TBL] [Abstract][Full Text] [Related]
76. Autocrine and paracrine motility factors and their involvement in invasiveness in a human oral carcinoma cell line.
Hasina R; Matsumoto K; Matsumoto-Taniura N; Kato I; Sakuda M; Nakamura T
Br J Cancer; 1999 Aug; 80(11):1708-17. PubMed ID: 10468286
[TBL] [Abstract][Full Text] [Related]
77. Transforming growth factor-alpha-Pseudomonas exotoxin fusion protein (TGF-alpha-PE38) treatment of subcutaneous and intracranial human glioma and medulloblastoma xenografts in athymic mice.
Phillips PC; Levow C; Catterall M; Colvin OM; Pastan I; Brem H
Cancer Res; 1994 Feb; 54(4):1008-15. PubMed ID: 8313355
[TBL] [Abstract][Full Text] [Related]
78. TGF-alpha-driven tumor growth is inhibited by an EGF receptor tyrosine kinase inhibitor.
El-Obeid A; Hesselager G; Westermark B; Nistér M
Biochem Biophys Res Commun; 2002 Jan; 290(1):349-58. PubMed ID: 11779176
[TBL] [Abstract][Full Text] [Related]
79. Blocking transforming growth factor-β signaling pathway augments antitumor effect of adoptive NK-92 cell therapy.
Yang B; Liu H; Shi W; Wang Z; Sun S; Zhang G; Hu Y; Liu T; Jiao S
Int Immunopharmacol; 2013 Oct; 17(2):198-204. PubMed ID: 23806302
[TBL] [Abstract][Full Text] [Related]
80. Marked inhibition of tumor growth in a malignant glioma tumor model by a novel synthetic matrix metalloproteinase inhibitor AG3340.
Price A; Shi Q; Morris D; Wilcox ME; Brasher PM; Rewcastle NB; Shalinsky D; Zou H; Appelt K; Johnston RN; Yong VW; Edwards D; Forsyth P
Clin Cancer Res; 1999 Apr; 5(4):845-54. PubMed ID: 10213221
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
